Stevanato Group (NYSE:STVN) Sees Large Volume Increase – Here’s What Happened

Stevanato Group S.p.A. (NYSE:STVN) shares saw an uptick in trading volume on Wednesday . 967,490 shares traded hands during mid-day trading, an increase of 176% from the previous session’s volume of 350,676 shares.The stock last traded at €20.64 ($21.50) and had previously closed at €20.91 ($21.78).

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Bank of America upped their price objective on Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Morgan Stanley reiterated an “equal weight” rating and set a $23.00 target price (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Finally, Wolfe Research assumed coverage on Stevanato Group in a research report on Friday, December 13th. They set an “outperform” rating and a $28.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of €28.60 ($29.79).

Stevanato Group Price Performance

The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. The company has a 50-day moving average price of €21.67 and a 200-day moving average price of €20.51. The firm has a market capitalization of $6.76 billion, a PE ratio of 47.47, a P/E/G ratio of 7.42 and a beta of 0.56.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.13 ($0.14) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The company had revenue of €277.90 million during the quarter, compared to analysts’ expectations of €274.36 million. During the same quarter in the prior year, the company earned $0.16 earnings per share. The firm’s revenue was up 2.4% compared to the same quarter last year. Sell-side analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Institutional Investors Weigh In On Stevanato Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in STVN. nVerses Capital LLC acquired a new stake in shares of Stevanato Group in the third quarter valued at about $84,000. Hardy Reed LLC grew its stake in shares of Stevanato Group by 8.2% in the third quarter. Hardy Reed LLC now owns 11,077 shares of the company’s stock valued at $222,000 after buying an additional 840 shares in the last quarter. Lindenwold Advisors INC grew its stake in shares of Stevanato Group by 13.5% in the third quarter. Lindenwold Advisors INC now owns 11,930 shares of the company’s stock valued at $239,000 after buying an additional 1,415 shares in the last quarter. Raymond James Trust N.A. grew its stake in shares of Stevanato Group by 22.6% in the third quarter. Raymond James Trust N.A. now owns 12,556 shares of the company’s stock valued at $251,000 after buying an additional 2,317 shares in the last quarter. Finally, Captrust Financial Advisors grew its stake in shares of Stevanato Group by 12.7% in the third quarter. Captrust Financial Advisors now owns 13,100 shares of the company’s stock valued at $262,000 after buying an additional 1,480 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.